← Back to Clinical Trials
Recruiting NCT07546331

NCT07546331 Novel Body Composition Measurements in Association With Outcomes of Breast Reconstruction Reconstruction

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07546331
Status Recruiting
Phase
Sponsor University of California, San Francisco
Condition Breast Carcinoma
Study Type OBSERVATIONAL
Enrollment 40 participants
Start Date 2026-02-18
Primary Completion 2028-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Measurement of Body CompositionChart Review

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 40 participants in total. It began in 2026-02-18 with a primary completion date of 2028-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study compares measurements of body composition to outcomes of breast reconstruction.

Eligibility Criteria

Inclusion Criteria: 1. Patients must have histologically confirmed breast malignancy or increased risk of developing a breast malignancy. 2. Age ≥ 18 years. 3. Scheduled to undergo mastectomy with immediate breast reconstruction using a permanent implant, tissue expander, or autologous tissue (e.g. Deep Inferior Epigastric Perforator (DIEP) flap, muscle-sparing Transverse Rectus Abdominis Myocutaneous (msTRAM) flap, Profunda Artery Perforator (PAP) flap). 4. Ability to understand a written informed consent document, and the willingness to sign it. Exclusion Criteria: 1. Any significant medical condition or laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study. 2. Pregnant or breastfeeding. 3. Patients assigned male at birth. 4. Non-cisgender women. 5. Patients with implanted electronic medical devices (e.g. pacemaker, defibrillator). 6. Patients with prosthetic limbs.

Contact & Investigator

Central Contact

Michael Choi

✉ Michael.Choi@ucsf.edu

📞 877-827-3222

Principal Investigator

Merisas Piper, MD

PRINCIPAL INVESTIGATOR

University of California, San Francisco

Frequently Asked Questions

Who can join the NCT07546331 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07546331 currently recruiting?

Yes, NCT07546331 is actively recruiting participants. Contact the research team at Michael.Choi@ucsf.edu for enrollment information.

Where is the NCT07546331 trial being conducted?

This trial is being conducted at San Francisco, United States.

Who is sponsoring the NCT07546331 clinical trial?

NCT07546331 is sponsored by University of California, San Francisco. The principal investigator is Merisas Piper, MD at University of California, San Francisco. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology